Bryce B Reeve1, Molly McFatrich1, Jennifer W Mack2, Laura C Pinheiro3, Shana S Jacobs4, Justin N Baker5, Janice S Withycombe6, Li Lin1, Courtney M Mann1, Katie R Villabroza7, Pamela S Hinds4. 1. Duke University School of Medicine, Durham, North Carolina. 2. Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, Massachusetts. 3. Well Cornell Medicine, New York, New York. 4. Children's National Health System, Washington, District of Columbia. 5. St. Jude Children's Research Hospital, Memphis, Tennessee. 6. Clemson University School of Nursing (formerly Emory University), Clemson, South Carolina. 7. Children's Hospital Los Angeles, Los Angeles, California.
Abstract
BACKGROUND: The Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric measures were designed to assess symptoms and functioning in children and adolescents. The study goal was to evaluate the validity and responsiveness of the PROMIS Pediatric measures in a diverse cohort of children with cancer. METHODS: Children (7-18 years) from nine pediatric oncology hospitals completed surveys at 72 hours preceding treatment initiation (T1) and at follow-up (T2) approximately 7 to 17 days later for chemotherapy, and 4+ weeks later for radiation. Children completed PROMIS Pediatric measures (Mobility, Pain Interference, Fatigue, Depressive Symptoms, Anxiety, Psychological Stress), Memorial Symptom Assessment Scale (MSAS), and global impressions of change (GIC) questions on their symptoms and functioning at T2 reflecting on T1. Parents completed the Lansky Play-Performance Status (PPS) scale and medication list for their child. RESULTS: The children (n = 482) were average age 12.9 years, 46% female, 60% Caucasian, and had diverse cancers and treatments. There were moderate to strong correlations between PROMIS Pediatric and MSAS, supporting convergent validity. In support for known-groups validity, the PROMIS Pediatric average scores were statistically different (P < 0.05) for most domains by PPS and if the child was on a medication (or not) for controlling a symptom. The PROMIS Pediatric measures were responsive over time in association with the GIC. CONCLUSIONS: In a large, diverse sample of children and adolescents with cancer, there was strong evidence for the construct validity and responsiveness of the PROMIS Pediatric measures. This evidence supports PROMIS Pediatric measure use in pediatric oncology trials.
BACKGROUND: The Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric measures were designed to assess symptoms and functioning in children and adolescents. The study goal was to evaluate the validity and responsiveness of the PROMIS Pediatric measures in a diverse cohort of children with cancer. METHODS:Children (7-18 years) from nine pediatric oncology hospitals completed surveys at 72 hours preceding treatment initiation (T1) and at follow-up (T2) approximately 7 to 17 days later for chemotherapy, and 4+ weeks later for radiation. Children completed PROMIS Pediatric measures (Mobility, Pain Interference, Fatigue, Depressive Symptoms, Anxiety, Psychological Stress), Memorial Symptom Assessment Scale (MSAS), and global impressions of change (GIC) questions on their symptoms and functioning at T2 reflecting on T1. Parents completed the Lansky Play-Performance Status (PPS) scale and medication list for their child. RESULTS: The children (n = 482) were average age 12.9 years, 46% female, 60% Caucasian, and had diverse cancers and treatments. There were moderate to strong correlations between PROMIS Pediatric and MSAS, supporting convergent validity. In support for known-groups validity, the PROMIS Pediatric average scores were statistically different (P < 0.05) for most domains by PPS and if the child was on a medication (or not) for controlling a symptom. The PROMIS Pediatric measures were responsive over time in association with the GIC. CONCLUSIONS: In a large, diverse sample of children and adolescents with cancer, there was strong evidence for the construct validity and responsiveness of the PROMIS Pediatric measures. This evidence supports PROMIS Pediatric measure use in pediatric oncology trials.
Authors: Jin-Shei Lai; Brian D Stucky; David Thissen; James W Varni; Esi Morgan DeWitt; Debra E Irwin; Karin B Yeatts; Darren A DeWalt Journal: Qual Life Res Date: 2013-02-02 Impact factor: 4.147
Authors: Lori Wiener; Anne E Kazak; Robert B Noll; Andrea Farkas Patenaude; Mary Jo Kupst Journal: Pediatr Blood Cancer Date: 2015-09-23 Impact factor: 3.167
Authors: David Cella; William Riley; Arthur Stone; Nan Rothrock; Bryce Reeve; Susan Yount; Dagmar Amtmann; Rita Bode; Daniel Buysse; Seung Choi; Karon Cook; Robert Devellis; Darren DeWalt; James F Fries; Richard Gershon; Elizabeth A Hahn; Jin-Shei Lai; Paul Pilkonis; Dennis Revicki; Matthias Rose; Kevin Weinfurt; Ron Hays Journal: J Clin Epidemiol Date: 2010-08-04 Impact factor: 6.437
Authors: Valerie McLaughlin Crabtree; Amanda M Rach; Kriston B Schellinger; Kathryn M Russell; Teresa Hammarback; Belinda N Mandrell Journal: Support Care Cancer Date: 2014-08-13 Impact factor: 3.603
Authors: David Thissen; Yang Liu; Brooke Magnus; Hally Quinn; Debbie S Gipson; Carlton Dampier; I-Chan Huang; Pamela S Hinds; David T Selewski; Bryce B Reeve; Heather E Gross; Darren A DeWalt Journal: Qual Life Res Date: 2015-06-29 Impact factor: 4.147
Authors: Darren A DeWalt; Heather E Gross; Debbie S Gipson; David T Selewski; Esi Morgan DeWitt; Carlton D Dampier; Pamela S Hinds; I-Chan Huang; David Thissen; James W Varni Journal: Qual Life Res Date: 2015-02-26 Impact factor: 4.147
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: David Cella; Susan Yount; Nan Rothrock; Richard Gershon; Karon Cook; Bryce Reeve; Deborah Ader; James F Fries; Bonnie Bruce; Mattias Rose Journal: Med Care Date: 2007-05 Impact factor: 2.983
Authors: John M Salsman; Suzanne C Danhauer; Justin B Moore; Mollie R Canzona; David E Victorson; Bradley J Zebrack; Bryce B Reeve Journal: Cancer Date: 2020-09-10 Impact factor: 6.860
Authors: Janice S Withycombe; Molly McFatrich; Pamela S Hinds; Antonia Bennett; Li Lin; Scott H Maurer; Nicole R Lucas; Courtney M Mann; Sharon M Castellino; Justin N Baker; Bryce B Reeve Journal: Cancer Nurs Date: 2022-02-05 Impact factor: 2.760
Authors: Gomolemo Mahakwe; Ensa Johnson; Katarina Karlsson; Stefan Nilsson Journal: Int J Environ Res Public Health Date: 2021-02-16 Impact factor: 3.390
Authors: Scott H Maurer; Pamela S Hinds; Bryce B Reeve; Jennifer W Mack; Molly McFatrich; Li Lin; Janice S Withycombe; Shana S Jacobs; Justin N Baker; Sharon M Castellino; David R Freyer Journal: Cancer Date: 2021-07-01 Impact factor: 6.921